NeuBase Therapeutics Inc. (NASDAQ:NBSE) traded with a subtraction of -$0.08 to $0.94 on Thursday, a downside of -7.85 percent. An average of 1,128,736 shares of common stock have been traded in the last five days. There was a gain of $0.2436 in the past week, and it reached a new high 1 time over the past 12 months. The last 20 days have seen an average of 512,964 shares traded, while the 50-day average volume stands at 293,175.
NBSE stock has decreased by -34.27% in the last month. The company shares reached their 1-month lowest point of $0.6050 on 08/18/23. With the stock rallying to its 52-week high on 02/13/23, shares of the company touched a low of $0.61 and a high of $17.00 in 52 weeks. It has reached a new high 9 times so far this year and lost -75.29% or -$2.8904 in price. In spite of this, the price is down -94.47% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
NeuBase Therapeutics Inc. (NBSEstock’s beta is 0.85. Other valuation ratios to consider include the price-to-book (PB) ratio at 0.14.
Financial Health
The quick ratio of NeuBase Therapeutics Inc. for the three months ended June 29 was 2.50, and the current ratio was 2.50, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Its gross profit as reported stood at $24000.0 compared to revenue of $33.32 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, NeuBase Therapeutics Inc.’s return on assets was -76.60%.
Earnings Surprise
In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$3.45 million in the quarter, while revenues of -$4.37 million were shrunk -107.54%. The analyst consensus anticipated NeuBase Therapeutics Inc.’s latest quarter earnings to come in at -$2 per share, but it turned out to be -$2.04, a -2.00% surprise. For the quarter, EBITDA amounted to -$3.38 million. Shareholders own equity worth $2.36 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at NeuBase Therapeutics Inc. (NBSE) price momentum. RSI 9-day as of the close on 23 August was 48.09%, suggesting the stock is Neutral, with historical volatility in this time frame at 178.14%.
As of today, NBSE’s price is $0.8444 +36.36% or $0.2436 from its 5-day moving average. NBSE is currently trading -30.79% lower than its 20-day SMA and -75.31% lower than its 100-day SMA. However, the stock’s current price level is -74.62% below the SMA50 and -83.28% below the SMA200.
The stochastic %K and %D were 60.92% and 44.49%, respectively, and the average true range (ATR) was 0.1662. With the 14-day stochastic at 54.62% and the average true range at 0.1775, the RSI (14) stands at 39.50%. The stock has reached 0.1537 on the 9-day MACD Oscillator while the 14-day reading was at 0.1186.
Analyst Ratings
H.C. Wainwright reiterated its a Buy rating on NeuBase Therapeutics Inc. (NASDAQ: NBSE), but raised their price target to $15, indicating a potential price increase of 93.73% for the stock. The consensus rating for NeuBase Therapeutics Inc. (NBSE) among analysts is Hold. According to current brokerage recommendations, 0 brokerage firms advise that investors sell NBSE, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 0 others rate it as a “buy”.
What is NBSE’s price target for the next 12 months?
Analysts predict a range of price targets between $200.00 and $200.00, with a median target of $200.00. Taking a look at these predictions, the average price target given by analysts for NeuBase Therapeutics Inc. (NBSE) stock is $200.00.
